Literature DB >> 20598845

Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands.

M W J M Wouters1, S Siesling, M L Jansen-Landheer, M A G Elferink, J Belderbos, J W Coebergh, F M N H Schramel.   

Abstract

BACKGROUND: Care processes for patients with NSCLC can vary by provider, which may lead to unwanted variation in outcomes. Therefore, in modern health care an increased focus on guideline development and implementation is seen. It is expected that more guideline adherence leads to a higher number of patients receiving optimal treatment for their cancer which could improve overall survival.
OBJECTIVE: The aim of this study was to evaluate variations in treatment patterns and outcomes of patients with NSCLC treated in different (types of) hospitals and regions in the Netherlands. Especially, variation in the percentage of patients receiving the optimal treatment for the stage of their disease, according to the Dutch national guideline of 2004, was analyzed.
METHODS: All patients with a histological confirmed primary NSCLC diagnosed in the period 2001-2006 in all Dutch hospitals (N = 97) were selected from the population-based Netherlands Cancer Registry. Hospitals were divided in groups based on their region (N = 9), annual volume of NSCLC patients, teaching status and presence of radiotherapy facilities. Stage-specific differences in optimal treatment rates between (groups of) hospitals and regions were evaluated.
RESULTS: In the study period 43 544 patients were diagnosed with NSCLC. The resection rates for stage I/II NSCLC patients increased during the study period, but resection rates varied by region and were higher in teaching hospitals for thoracic surgeons (OR 1.5; 95%CI 1.2-1.9, p = 0.001) and in hospitals with a diagnostic volume of more than 50/year (OR 1.3; 95%CI 1.1-1.5, p = 0.001). Also the use of chemoradiation in stage III patients increased, though marked differences between hospitals in the use of chemoradiation for stage III patients were revealed. Differences in optimal treatment rates between hospitals led to differences in survival.
CONCLUSION: Treatment patterns and outcome of NSCLC patients in the Netherlands varied by region and the hospital their cancer was diagnosed in. Though resection rates were higher in hospitals training thoracic surgeons, variation between individual hospitals was much more distinct. Hospital characteristics like a high diagnostic volume, teaching status or availability of radiotherapy facilities proved no guarantee for optimal treatment rates. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20598845     DOI: 10.1016/j.ejso.2010.06.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  25 in total

1.  Reflections on the 14th World Conference on Lung Cancer: A European Perspective.

Authors:  Suresh Senan; Pieter E Postmus
Journal:  Oncologist       Date:  2012-02-21

2.  Measuring, Reporting, and Rewarding Quality of Care in 5 Nations: 5 Policy Levers to Enhance Hospital Quality Accountability.

Authors:  Christoph Pross; Alexander Geissler; Reinhard Busse
Journal:  Milbank Q       Date:  2017-03       Impact factor: 4.911

Review 3.  Multicriteria decision analysis in oncology.

Authors:  Georges Adunlin; Vakaramoko Diaby; Alberto J Montero; Hong Xiao
Journal:  Health Expect       Date:  2014-03-17       Impact factor: 3.377

4.  Readiness for Implementation of Lung Cancer Screening. A National Survey of Veterans Affairs Pulmonologists.

Authors:  Melissa H Tukey; Jack A Clark; Rendelle Bolton; Michael J Kelley; Christopher G Slatore; David H Au; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2016-10

5.  Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies.

Authors:  Suresh Senan; David A Palma; Frank J Lagerwaard
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

6.  The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry.

Authors:  Rob G Stirling; S M Evans; P McLaughlin; M Senthuren; J Millar; J Gooi; L Irving; P Mitchell; A Haydon; J Ruben; M Conron; T Leong; N Watkins; J J McNeil
Journal:  Lung       Date:  2014-06-08       Impact factor: 2.584

7.  Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base.

Authors:  John N Melvan; Manu S Sancheti; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez
Journal:  J Am Coll Surg       Date:  2015-04-16       Impact factor: 6.113

8.  Uptake of Video-Assisted Thoracoscopic Lung Resections Within the Veterans Affairs for Known or Suspected Lung Cancer.

Authors:  Amelia W Maiga; Stephen A Deppen; Jason Denton; Michael E Matheny; Erin A Gillaspie; Jonathan C Nesbitt; Eric L Grogan
Journal:  JAMA Surg       Date:  2019-06-01       Impact factor: 14.766

9.  Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.

Authors:  Rezwanul Hasan Rana; Fariha Alam; Khorshed Alam; Jeff Gow
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-03       Impact factor: 4.553

10.  Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

Authors:  Pamela Samson; Aalok Patel; Traves D Crabtree; Daniel Morgensztern; Cliff G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-07-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.